Revolution Medicines disclosed full Phase 3 results for daraxonrasib in previously treated, metastatic pancreatic ductal adenocarcinoma at ASCO 2026, with the data simultaneously published in The New England Journal of Medicine. The pan-RAS inhibitor reduced the risk of death versus standard chemotherapy and drove survival and disease-control gains across key subgroups. In the RASolute 302 study, Revolution reported a median overall survival of 13.2 months in the daraxonrasib arm versus 6.7 months with chemotherapy in the all-comer population, with similarly large separation in RAS G12-mutant patients. Investigators also highlighted improvements in progression-related endpoints and supportive tolerability observations. The presentation included subgroup detail that extends beyond a single genotype, positioning daraxonrasib as a potentially practice-changing option in second-line metastatic pancreatic cancer pending regulatory and further confirmatory work.